Marinus Pharmaceuticals sees FY23 U.S. ZTALMY revenue $19.5M-$19.7M

Marinus Pharmaceuticals reported business highlights and preliminary U.S. ZTALMY net product revenue for the fourth quarter and year ended December 31 …ZTALMY or ganaxolone, Q4 2023 preliminary net product revenue of between $6.5 and $6.7M; full year 2023 preliminary net product revenue of between $19.5 and $19.7M; Projected full year 2024 U.S. ZTALMY net product revenue of between $32 and $34M ;Over 90% of patients required for the interim analysis are now enrolled in the RAISE trial..TrustTSC trial enrollment now over 70%; enrollment completion anticipated by end of Q1 and topline data anticipated in Q3 2024 ..Cash runway projected into Q4 2024 with preliminary unaudited cash, cash equivalents and short-term investments of $150.3M as of December 31. “Our commercial strategy and deep understanding of the epilepsy and rare disease space continues to drive increasing adoption of ZTALMY, establishing a strong foundation for the future of the franchise and positioning us to generate robust growth in the year ahead,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. “We expect 2024 will be another pivotal year for Marinus with two Phase 3 data readouts anticipated, beginning with topline data from the RAISE trial of IV ganaxolone in refractory status epilepticus in the second quarter followed by the TrustTSC study readout in tuberous sclerosis complex in the third quarter. We have an opportunity to address significant unmet needs in patients with refractory seizure disorders and remain committed to developing potentially lifesaving treatments.”